UBS Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-8,477
| Closed | -$31.8K | – | 10733 |
|
|
2024
Q3 | $31.8K | Buy |
8,477
+8,474
| +282,467% | +$48.7K | ﹤0.01% | 7099 |
|
|
2024
Q2 | $30 | Sell |
3
-76
| -96% | -$2.56K | ﹤0.01% | 9276 |
|
|
2024
Q1 | $6.01K | Buy |
79
+76
| +2,533% | +$10K | ﹤0.01% | 7490 |
|
|
2023
Q4 | $565 | Buy |
3
+2
| +200% | +$984 | ﹤0.01% | 8585 |
|
|
2023
Q3 | $410 | Hold |
1
| – | – | ﹤0.01% | 8515 |
|
|
2023
Q2 | $2.75K | Hold |
1
| – | – | ﹤0.01% | 7707 |
|
|
2023
Q1 | $1.54K | Sell |
1
-2
| -67% | -$5.86K | ﹤0.01% | 8713 |
|
|
2022
Q4 | $6.63K | Sell |
3
-3
| -50% | -$10.5K | ﹤0.01% | 9010 |
|
|
2022
Q3 | $24K | Buy |
6
+5
| +500% | +$19.7K | ﹤0.01% | 7170 |
|
|
2022
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 9653 |
|
|
2022
Q1 | $3K | Sell |
1
-10
| -91% | -$43K | ﹤0.01% | 9512 |
|
|
2021
Q4 | $70K | Buy |
11
+10
| +1,000% | +$76.8K | ﹤0.01% | 6631 |
|
|
2021
Q3 | $7K | Buy |
+1
| New | +$8.59K | ﹤0.01% | 8347 |
|
|
2021
Q2 | – | Sell |
-2
| Closed | -$32.9K | – | 9936 |
|
|
2021
Q1 | $43K | Buy |
+2
| New | +$23.3K | ﹤0.01% | 6706 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 8859 |
|
|
2020
Q3 | – | Sell |
-1
| Closed | -$3.59K | – | 8509 |
|
|
2020
Q2 | $4K | Sell |
1
-2
| -67% | -$6.64K | ﹤0.01% | 7489 |
|
|
2020
Q1 | $6K | Buy |
+3
| New | +$11.2K | ﹤0.01% | 7246 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 8481 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 8333 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 8226 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7359 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7431 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7762 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 8325 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 8241 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7735 |
|
|
2017
Q3 | – | Hold |
0
| – | -$9K | – | 8064 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6858 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7478 |
|
|
2016
Q4 | – | Hold |
0
| – | -$1K | – | 8103 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7552 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7583 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6505 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 8037 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 7857 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8226 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 8026 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 8414 |
|
Other funds holding SEEL
UBS Group's SEEL Position: Q4 2024 in Review
UBS Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 8,477 shares — an estimated $31.8K sold.
UBS Group first reported a position in SEEL in Q1 2020 and held it in 16 quarters. The position peaked at $70K in Q4 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- UBS Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 8,477 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $31.8K.
- UBS Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
- UBS Group's Seelos Therapeutics, Inc. Common Stock position peaked at $70K in Q4 2021.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.